A quinazolinone is a bicyclic heterocyclic compound built on a benzene ring fused to a pyrimidine ring, with a carbonyl group at position 4 of the pyrimidine.[1] The class is defined by this shared chemical scaffold rather than by a single pharmacological action, though the psychoactive members all share the same sedative-hypnotic, GABA-A-targeting profile.
The psychoactive subset of the scaffold is narrow. Both known members — methaqualone and mephenaqualone — are 2,3-disubstituted 4(3H)-quinazolinones differing only at a single ring substituent, and both converge on the same sedative-hypnotic action through the same GABA-A receptor site.[2]
Methaqualone is the prototypical and best-studied member; it was marketed in the late 1950s and 1960s as Quaalude and Mandrax for the treatment of insomnia before recreational abuse and dependence led to its withdrawal from most legal markets and Schedule I placement in the United States.[3]
Across the dose range, members produce anxiolysis and mild euphoria at lower exposures, deepening sedation and motor impairment as the dose rises, and hypnosis or coma at the high end.
Pharmacology
Across the class, the shared mechanism is positive allosteric modulation (PAM) of GABA-A receptors — the principal ligand-gated chloride channels carrying fast inhibitory neurotransmission in the central nervous system.[2] Quinazolinones enhance the response of the receptor to endogenous GABA, raising chloride conductance and net neuronal inhibition.
| Mechanism | Representative members | How it reaches the shared endpoint |
|---|---|---|
| GABAA positive allosteric modulation at the β(+)/α(−) transmembrane interface | methaqualone, mephenaqualone | Deep insertion at the β/α intersubunit site widens the channel pore and destabilizes the hydrophobic activation gate, potentiating GABA-driven chloride flux[4] |
The binding site distinguishes the class from other GABAergic sedative-hypnotics. Quinazolinones do not bind at the benzodiazepine site, the barbiturate site, or the neurosteroid site; cryo-EM data localize their binding to the β/α transmembrane interface — the same class of intersubunit transmembrane site occupied by the general anaesthetics etomidate and propofol, though quinazolinones insert more deeply and form hydrogen bonds at β2N265.[4]
The mechanistic detail matters less for safety than the convergent endpoint: regardless of the binding route, the class enhances inhibitory tone and dose-dependently suppresses arousal and respiratory drive. A pharmacologically distinctive feature is that quinazolinones act as robust positive modulators at α1,2,3,5β2,3γ2S synaptic receptors but show subtype-contingent behaviour at δ-containing extrasynaptic receptors, where they range from inactive to negatively modulating to superagonist.[2] This heterogeneous receptor profile may underlie the unusual mixed clinical picture of sedation alongside paradoxical excitatory phenomena at higher doses.
Substances
The psychoactive scaffold is represented by two close structural analogues; the class is small, and methaqualone supplies most of the available pharmacological characterization.
| Member | Subgroup | Role / distinctive feature |
|---|---|---|
| Methaqualone | 2-methyl-3-(o-tolyl)-4(3H)-quinazolinone | The prototypical member; marketed as Quaalude and Mandrax in the 1960s–70s, later Schedule I after widespread abuse[3] |
| Mephenaqualone | 2-methyl-3-(2-bromophenyl)-4(3H)-quinazolinone | A close structural analogue appearing as a designer drug; pharmacology inferred from the shared scaffold rather than independently characterized |
The two members differ only at the N-3 aryl substituent, and the available evidence supports treating them as a single pharmacological group for the purposes of mechanism and safety — though specific receptor-subtype and clinical data are well-established only for methaqualone.
Subjective Effects
The class produces a recognizable trajectory of progressive CNS depression, marked at the lower end by a disinhibition-and-euphoria phase that was historically unusual for a sedative-hypnotic and helped drive recreational use.[2]
| Exposure | Characteristic effects |
|---|---|
| Low | Anxiolysis, mild euphoria, disinhibition, relaxation, and an early drop in motor coordination |
| Moderate–high | Deepening sedation, pronounced muscle relaxation, slurred speech, ataxia, and severe cognitive and psychomotor impairment |
| High | Hypnosis progressing toward loss of consciousness and coma, with paradoxical neuromuscular hyperactivity (hyperreflexia, myoclonus, twitching) appearing alongside the depressant features[2] |
The same GABA-A axis drives both the sought effects (relaxation, euphoria, sleep) and the dangerous ones (loss of airway reflexes, respiratory depression, neuromuscular instability), and the margin between heavy sedation and life-threatening toxicity narrows as exposure rises or as other depressants are stacked on top.
Safety
Risk profile
The defining acute danger of the class is additive CNS and respiratory depression. Combining a quinazolinone with another depressant — alcohol, opioids, benzodiazepines, barbiturates, or gabapentinoids — sharply raises the risk of fatal respiratory failure compared with any single agent. Historical methaqualone fatalities frequently involved co-use with alcohol.
Severe quinazolinone overdose differs from the textbook barbiturate or benzodiazepine picture in one important respect: pure respiratory depression is less prominent than with barbiturates at comparable sedative loads, while neuromuscular hyperactivity — hypertonia, hyperreflexia, myoclonus, and convulsions — plays a larger role than the depressant-class analogy would predict.[2] Severe presentations can include delirium, convulsions, kidney failure, and death from cardiac or respiratory arrest.
There is no specific antidote: naloxone does not reverse GABA-A-mediated depression, and the mainstays of clinical care are airway management and symptomatic control of neuromuscular instability. Severe motor incoordination and cognitive impairment even at moderate doses also raise the risk of accidents, falls, and aspiration.
Tolerance & dependence
Tolerance to quinazolinone effects develops with regular use; in the methaqualone era, escalation to high daily intake within days of sustained use was documented.[3] Because the mechanism converges on GABA-A potentiation, cross-tolerance is established with the broader GABAergic sedative-hypnotic family — benzodiazepines, barbiturates, alcohol, and GHB — and cross-dependence supports the use of long-acting GABAergic agents in withdrawal management.[5] Both physical and psychological dependence develop with sustained use; the euphoric, disinhibiting quality at sub-hypnotic doses underwrites a substantial psychological component on top of the physiological adaptation.
Quinazolinone withdrawal after established physical dependence can itself be life-threatening. The syndrome shares the character of alcohol and barbiturate withdrawal — anxiety, insomnia, tremors, myoclonus, diaphoresis, and in severe cases hyperthermia, toxic psychosis, and generalized seizures — driven by the same rebound shift toward excitatory tone after chronic GABAergic potentiation.[5] People physically dependent on a quinazolinone should not stop abruptly without medical supervision.
Recovery
Recovery from quinazolinone dependence follows the well-trodden clinical pathway for GABAergic sedative-hypnotics. A medically supervised taper — typically substituting a longer-acting GABAergic agent such as a long-acting benzodiazepine or phenobarbital and reducing the dose gradually — is the established approach, and cross-dependence means a safe taper can be structured even where the specific quinazolinone is unavailable.[5]Acute symptoms peak in the first days after cessation, with mood and sleep disturbance resolving over weeks to months. If you or someone you know is dependent on a quinazolinone, a clinician or withdrawal-management service can structure a safe taper.
Recovery resources, crisis lines, and support pathways → View all
Members
references
- [1]^Asif, M. (2014) Chemical Characteristics, Synthetic Methods, and Biological Potential of Quinazoline and Quinazolinone Derivatives — International Journal of Medicinal Chemistry doi:10.1155/2014/395637
- [2]^abcdefHammer H, Bader BM, Ehnert C, Bundgaard C, Bunch L, Hoestgaard-Jensen K, Schroeder OH, Bastlund JF, Gramowski-Voss A, Jensen AA (2015) A Multifaceted GABAA Receptor Modulator: Functional Properties and Mechanism of Action of the Sedative-Hypnotic and Recreational Drug Methaqualone (Quaalude) — Molecular Pharmacology doi:10.1124/mol.115.099291
- [3]^abcIonescu-Pioggia, M. and Bird, M. and Orzack, M.H. and Benes, F. and Beake, B. and Cole, J.O. (1988) Methaqualone — International Clinical Psychopharmacology doi:10.1097/00004850-198804000-00001
- [4]^abcChojnacka W, Teng J, Kim JJ, Jensen AA, Hibbs RE (2024) Structural insights into GABAA receptor potentiation by Quaalude — Nature Communications doi:10.1038/s41467-024-49471-y
- [5]^abcSantos, C. and Olmedo, R.E. (2017) Sedative-Hypnotic Drug Withdrawal Syndrome: Recognition And Treatment — Emergency Medicine Practice PMID:28186869